1. Straub NC. Pulmonary edema due to increased microvascular permeability to fluid and protein. Circ. Res. 1978; 43:143-151.
2. Newman SP. Scintigraphic assessment of therapeutic aerosols. Crit. Rev. Therapeut. Drug Carrier Syst. 1993; 10:65-109.
3. DiSousa S. The Montreal protocol and essential use exemptions. J. Aerosol Med. 1995; 8:S13-17.
4. Bisgaard H. Delivery of inhaled medication to children. J. Asthma 1997; 34:443-467.
5. Ashworth HL, Wilson CG, Sims EE, Wooton PK, Hardy JG. Delivery of propellant soluble drug from a metered dose inhaler. Thorax 1991; 46:245-247.
6. Harnor KJ, Perkins AC, Wastie ML, Wilson CG, Sims EE, Feely LC, Fair SJ.. Effect of vapour pressure on the deposition pattern from solution phase metered dose inhalers. Int. J. Pharmaceut. 1993; 95:111-116.
7. Leach C. Enhanced drug delivery through reformulating MDIs with HFA propellants— drug deposition and its effect on preclinical and clinical programs. In Respiratory drug delivery V Dalby, R.N., Byron, PR. Fair, S.J (eds). Buffalo Grove, Interpharm Press 1996:133-144.
8. Newman SP, Weisz AWB, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991; 46:712-716.
9. Pitcairn GR, Hunt HMA, Dewberry H, Pavia D, Newman SP. A comparison of in vitro drug delivery from two dry powder inhalers, the Aerohaler and the Rotohaler. STP Pharma Sciences 1994; 4:33-37.
10. Lipworth BJ, Clark DJ. Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices. Europ. J. Clin. Pharmacol. 1997; 53:47-49.
11. Vidgren MT, Kärkkäinen A, Paronen TP, Karjalainen P. Respiratory tract deposition of 99mTc-labelled drug particles administered via a drug powder inhaler. Int. J. Pharmaceut. 1987; 39:101-105.
12. Hardy JG, Newman SP, Knock M. Lung deposition from four nebulizers. Resp. Med. 1993; 87:461-465.
13. Fair SJ, Ho KKL, Kellaway IW. A gamma scintigraphic study of tracheo-bronchial deposition and clearance of nebulised aerosols. STP Pharma Sci. 1994; 4:23-28.
14. Newman SJ, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines. Chest 1998; 113:957963.
15. Kenyon CJ, Thorsson L, Borgstrom L, Newman SP. The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients. Europ. Respir. J. 1998; 11:606-610.
16. Gonda I, Schuster JA, Rubsamen RM, Lloyd P, Cipolla D, Fair SJ. Inhalation delivery systems with compliance and disease management capabilities. J. Cont. Rel. 1998; 53:269-274.
17. Fair SJ, Rowe AM, Rubsamen R, Taylor G. Aerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhaler. Thorax 1995; 50:639-644.
18. Newman SP, Wilding IR. Gamma scintigraphy: an in vivo technique for assessing the equivalence of inhaled products. Int. J. Pharmaceut. 1998; 170:1-9.
19. Perring S, Summers Q, Fleming JS, Nassim MA, Holgate ST. A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler. Br. J. Radiol. 1994; 67:46-53.
20. Isitman AT, Manoli R, Schmidt GH, Holmes RA. An assessment of alveolar deposition and pulmonary clearance of radiopharmaceuticals after nebulization. Am. J. Roentgenol. Radium Ther. Nucl. Med. 1974; 120:776-781.
21. Wilson CG, Washington N, Washington C, Frier M, Poole S, Yeadon M. Investigation into the disposition and clearance of an artificial lung surfactant when delivered by aerosol or intratracheal instillation. Pharmaceut. Sci. 1995; 1:271-275.
22. Short MD, Singh CA, Few JD, Studdy PT, Heaf PJD, Spiro SG. The labelling and monitoring ofan inhaled, synthetic, anticholinergic bronchodilating agent . Chest 1981; 80:918-921.
23. Borgstrom L, Newman S. Total and regional lung deposition of terbutaline sulphate inhaled via a pressurised MDI or via a Turbuhaler. Int. J. Pharmaceut. 1993; 97:47-53.
24. Arppe J, Vidgren M. Practical gamma labelling method for metered-dose inhalers and inhalation powders. STP Pharma Sciences 1994; 4:19-22.
25. Raabe OG, Howard RS, Cross CE. In Bronchial Asthma Gershwin M.E. (ed), Grune and Stratton, London and New York. 1986:495-514.
26. Gonda I. A semi-empirical model of aerosol deposition in the human respiratory tract for mouth inhalation. J. Pharm. Pharmacol. 1981; 33:692-696.
27. Moren F, Andersson J. Fraction of dose exhaled after administration of pressurised inhalation aerosols. Int. J. Pharmaceut. 1980; 6:295-300.
28. Newman SP, Moren F, Trofast E, N. T, Clarke SW. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. Europ. Respir. J. 1989; 2:247-252.
29. Oliver S, Rees PJ. Use in chronic obstructive pulmonary disease. Int. J. Clin. Pract. 1997; 51:443-445.
30. Newman SP, Pavia D, Clarke SW. Simple instructions for using pressurized aerosol bronchodilators. J. Royal Soc. Med. 1980; 73:776-779.
31. Coady TJ, Davies HJ, Barnes P. Evaluation of a breath actuated pressurized aerosol. Clin. Allergy 1976; 6:1-6.
32. Melchor R, Biddiscombe MF, Mak VHF, Short MD, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and patients with reversible airflow obstruction. Thirax 1993; 48:506-511.
33. Saari SM, Vidgren MT, Koskinen MO, Turjanmaa VM, Waldrep JC, Nieminen MM. Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 1998; 113:1573-1579.
34. Taylor AE, Guyton AC, Bishop VS. Permeability of the alveolar membrane to solutes. Circ. Res. 1965; 16:352-362.
35. Pauwels R. Pharmacokinetics of inhaled drugs. In Aerosols in Medicine. Principles, Diagnosis and Therapy, Moren S, Newhouse MT, Elsevier, Biomedical Sciences Division 1985.
36. Walker SR, Evans ME, Richards AJ, Paterson JW. The clinical pharmacology of oral and inhaled salbutamol. Clin. Pharmacol. Ther. 1972; 13:861-867.
37. Nilson HT, Simonsson BG, Strom B. The fate of 3H-terbutaline sulphate administered to man as an aerosol. Eur. J. Clin. Pharmacol. 1976; 10:1-7.
39. Richards IM, Dixon M, Jackson DM, Vendy K. Alternative modes of action of sodium cromoglycate. Agents and Actions 1986; 18:294-300.
40. Riley PA, Mather ME, Keogh RW, Eady RP. Activity of neocromil sodium in mast cell dependent reactions in the rat. Int. Arch. Allergy Appl. Immunol. 1987; 82:108-110.
41. Clarke SW, Newman SP. Therapeutic aerosols 2-Drugs available by the inhaled route. Thorax 1984; 39:1-7.
42. Martin R, Litt M, Marriott C. The effect of mucolytic agents on the rheological and transport properties of canine tracheal mucus. Am. Rev. Resp. Dis. 1980; 121:495-500.
43. Palmer KNV. Reduction of sputum viscosity by a water aerosol in bronchitis. Lancet 1960; 1:91.
44. Shoeffel RE, Anderson SA, Attounyan REC. Bronchial hyper-reactivity in response to inhalation of ultrasonically nebulized solutions of distilled water and saline. Br. Med. J. 1981; 283:1285-1287.
45. Nadel JA. New approaches on regulation of fluid secretions in airways. Chest 1981; 80:849-851.
46. Clarke SW, Lopez-Vidriero MT, Pavia D, Thomson ML. The effect of sodium-2-mercaptoethane sulphonate and hypertonic saline aerosols on bronchial clearance in chronic bronchitis. Br. J. Clin. Pharmacol. 1979; 7:39-44.
47. Lightowler JE, Lightowler NM. Comparative mucolytic studies on dithiothreitol, N-acetylcysteine and L-cysteine on human respiratory mucus in vitro and their effects on the role of flow of mucus in the exposed trachea of the rat on topical administration. Arch. Int. Pharmacodyn. Ther. 1971; 189:53-58.
48. Marriott C, Kellaway IW. The effect of tetracyclines on the viscoelastic properties of bronchial mucus. Biorheol. 1975; 12:391-395.
49. Wigley FM, Fruchtman MH, Waldman RH. Aerosol immunisation of humans with inactivatedparainfluenza type 2 vaccine . N. Engl. J. Med. 1970; 283:1250-1253.
50. Colthorpe P, Fair SJ, Taylor G, Smith IJ, Wyatt D. The pharmacokinetics of pulmonary-delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharmaceut. Res. 1992; 9:764-768.
51. Colthorpe P, Fair SJ, Smith IJ, Wyatt D, Taylor G. The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabbits. Pharmaceut. Res. 1995; 12:356-359.
Ocular Drug Delivery
Was this article helpful?
Do You Suffer From ASTHMA Chronic asthma is a paralyzing, suffocating and socially isolating condition that can cause anxiety that can trigger even more attacks. Before you know it you are caught in a vicious cycle Put an end to the dependence on inhalers, buying expensive prescription drugs and avoidance of allergenic situations and animals. Get control of your life again and Deal With Asthma Naturally